Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway

Circulation

Volumn 102, Issue 18, 2000, Pages 2190-2196

  Brown, Nancy J ^a,c   Gainer, James V ^a   Murphey, Laine J ^a   Vaughan, Douglas E ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bradykinin; Endothelium; Endothelium derived factors; Nitric oxide synthase; Plasminogen activators

Indexed keywords

ACETYLCHOLINE; BRADYKININ; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ICATIBANT; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; THROMBOXANE B2; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0034739482     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.18.2190     Document Type: Article

References (41)

1. Endothelium and control of vascular function: State of the art lecture
2. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril
3. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation
4. Tissue plasminogen activator release in vivo in response to vasoactive agents
5. An endothelial storage granule for tissue-type plasminogen activator
6. Bradykinin stimulates tissue plasminogen activator release in human vasculature
7. Hoe 140 a new potent and long acting bradykinin antagonist: In vivo studies
8. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension
9. 2-receptor antagonist
10. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
11. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a signal transduction pathway
12. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin
13. Baseline fibrinolytic state and the risk of future venous thrombosis: A prospective study of endogenous tissue plasminogen activator and plasminogen activator inhibitor
14. Vascular-bed-specific hemostasis and hypercoagulable states
15. Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells
16. On the role of bradykinin in secretion from vascular endothelial cells
17. Activation of the plasma kallikrein/kinin system on endothelial cells
18. Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats
19. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery
20. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
21. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm
22. An in wvo model for the assessment of acute fibrinolytic capacity of the endothelium
23. Bradykinin induced tissue plasminogen activator release is enhanced by angiotensin converting enzyme inhibition but not angiotensin II receptor antagonism in healthy man
24. Effect of N(G)-monomethyl-L-arginine on kinin-induced vasodilation ill the human forearm
25. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man
26. The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor
27. Substance P and bradykinin activate different types of KCa currents to hyperpolarize cultured porcine coronary artery endothelial cells
28. Characterization of endothelium-derived relaxing factors released by bradykinin in human resistance arteries
29. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries
30. + channels
31. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm
32. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase
33. Superoxide anion is an endothelium-derived contracting factor
34. Hyperpolarizing factors
35. Cytochrome P450 2C is an EDHF synthase in coronary arteries
36. Importance of endothelium-derived hyperpolarizing factor in human arteries
37. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients
38. Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens
39. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects
40. Myocardial bradykinin production during coronary balloon angioplasty in humans
41. Role of endogenous bradykinin in human coronary vasomotor control